Domainex was established in 2001 as a spin-out of the Institute of Cancer Research in London and since this time has developed a superb track record in all phases of drug discovery. This has resulted in a record which surpasses that of the majority of its competitors, with 3 novel drug candidates entering clinical trials in the last 4 years (1 now in phase II), with 2 additional NCEs currently in advanced preclinical testing.
Domainex’s technology platform and service offering includes target protein expression, biochemical assay development, hit identification and integrated medicinal and computational chemistry to enable advancement to Candidate Drug (CD). It also routinely provides drug discovery advice to its clients and can aid decision making on route to CD. Furthermore, Domainex's strategic alliance with Pharmidex allows seamless integration of their state-of-the-art capabilities in pharmacokinetics into our drug discovery programmes.
Domainex believes that its highly-skilled scientists can accelerate client projects from target through to clinical candidate by applying the full range of drug discovery skills which they have refined during many years of pharmaceutical industry experience, together with proprietary technologies.
Domainex’s medicinal chemists are all highly-experienced drug hunters. Over 90% of its employees have PhDs, accompanied by significant industrial experience prior to joining Domainex. This experience has been gained at many well-known pharma and biotech companies such as GSK, AstraZeneca, Celltech, Astex, DeNovo, Medivir, Millennium, Rhone-Poulenc, Takeda, and UCB. Consequently the team have a great breadth of expertise across a wide range of targets including kinases, proteases, epigenetic enzymes, protein-protein interactions, GPCRs, cytokine receptors, growth factor receptors, integrins, ion channels; and in numerous therapeutic areas including oncology, respiratory, inflammation, CNS, and cardiovascular disorders.